{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"5.5","value":"3.6"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"10.6","value":"3.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"description":"Time to major erythroid response (MER) is defined in responders as the time from randomization to the documented date of MER.\n\nFor transfusion independent patients, the date of MER is the first date of the elevation in hemoglobin level of more than 2 g/dL that has been sustained for at least 8 weeks. For transfusion dependent patients, the date of MER is the beginning date of the time interval of transfusion independence that has been sustained for at least eight weeks.","dispersionType":"Full Range","groups":[{"description":"Patients receive lenalidomide PO QD on days 1-21.","id":"OG000","title":"Arm A (Lenalidomide; Randomization)"},{"description":"Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa SC once weekly.","id":"OG001","title":"Arm B (Lenalidomide + Epoetin Alfa; Randomization)"}],"paramType":"MEDIAN","populationDescription":"Only evaluable patients who achieved MER among randomized patients were included in this analysis.","reportingStatus":"POSTED","timeFrame":"Assessed every cycle during treatment and then 3 and 6 months after last protocol treatment","title":"Time to Major Erythroid Response (MER)","type":"SECONDARY","unitOfMeasure":"months"}